[Pubmed] Eculizumab in myasthenia gravis: A review

[RSS-Bot]

Saudi J Ophthalmol. 2024 Jan 6;38(1):34-40. doi: 10.4103/sjopt.sjopt_74_23. eCollection 2024 Jan-Mar.

ABSTRACT

Eculizumab, a monoclonal antibody against complement C5, is a novel therapy to treat refractory myasthenia gravis (MG). The present review was undertaken to study the role of eculizumab in MG. This includes the drug's mechanism, pharmacokinetics, clinical trial findings, tolerability, side effects, safety, dosage, administration, and cost. An English-language search for relevant items was undertaken using Embase and PubMed from 1946 to present. Clinical trial registries/databases and websites were also searched for relevant data. Keywords were eculizumab and MG. The present review found 103 articles after initial screening. Current data support eculizumab as an effective, safe, and tolerable drug in cases of refractory MG. However, its cost can prevent it from being widely accessible to a majority of the general population.

PMID:38628404 | PMC:PMC11016999 | DOI:10.4103/sjopt.sjopt_74_23


Source: https://pubmed.ncbi.nlm.nih.gov/3862840 ... t9+e462414